-
2023-507015-35-00
5
2023-10-06
Coronary Artery Disease
-
2022-502369-10-00
5
2023-10-02
Triple negative metastatic breast cancer
-
2022-502322-41-00
5
2023-09-12
Metastatic breast cancer
-
2023-503844-14-00
1
2023-06-13
Advanced Solid Tumors
-
2022-501352-28-00
5
2023-06-07
Severe community-acquired pneumonia (sCAP)
-
2022-502145-10-00
5
2023-06-06
Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor
-
2024-511023-34-00
10
2023-05-05
HER2-neg/low metastatic breast cancer
-
2024-514080-25-00
5
2023-04-21
Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary P
-
2023-505552-22-00
5
2023-02-24
Stage I-III Triple-negative Breast Cancer with residual invasive disea
-
2023-509825-38-00
5
2022-12-01
Metastatic Non–Small Cell Lung Cancer
-
2023-509429-37-00
5
2022-10-03
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2023-507933-12-00
5
2022-08-18
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
-
2024-513611-28-00
4
2022-07-29
Metastatic Solid Tumors
-
2022-500014-26-00
5
2022-06-24
Locally-Advanced unresectable or Metastatic breast cancer (MBC)
-
2023-508897-27-00
5
2022-04-28
Multiple Myeloma
-
2023-506361-56-00
5
2022-04-01
Endometrial cancer
-
2023-509466-38-00
5
2022-03-08
Cancer
-
2023-503640-14-00
5
2022-02-17
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
-
2023-507286-25-00
4
2021-12-23
Diffuse Large B-Cell Lymphoma
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-506518-33-00
5
2021-11-10
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-
2023-509208-14-00
5
2021-09-28
MULTIPLE MYELOMA
-
2024-514905-79-00
9
2021-09-17
Metastatic pancreatic ductal adenocarcinoma
-
2023-505249-24-00
5
2021-05-27
HER2-positive metastatic breast cancer